The Neurofibromatosis Therapeutic Consortium (NFTC)

Download Profile PDF
At a Glance
  • Status: Completed Consortium
  • Year Launched: 2013
  • Initiating Organization: The Children’s Tumor Foundation
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Neurofibromatosis
  • Location: North America

Abstract

The Neurofibromatosis Therapeutic Consortium (NFTC) brought together four labs to find novel targets for clinical trials. These two consortia cooperated to perform and complete 111 preclinical trials across different models. These studies identified 12 drug targets with promising efficacy, and 16 clinical trials have occurred based on the veracious preclinical data gathered by NFPC and NFTC investigators.

Mission

The NFTC was focused on NF1 and included sites investigating animal models of plexiform neurofibromas, MPNSTs, and NF1- associated leukemia. To continue the NFPC’s work on NF2, the Foundation launched the Synodos initiative.

Consortium History

The NFTC (NF Therapeutic Consortium) was launched at the conclusion of the NFPC as a three year $4 million program to follow up the work of the NFPC. The NFTC was focused on NF1 and included sites investigating animal models of plexiform neurofibromas, MPNSTs, and NF1- associated leukemia. To continue the NFPC’s work on NF2, the foundation launched the Synodos initiative.

Structure & Governance

The NFTC was created and run by the Children’s Tumor Foundation and then continued as the Synodos initiative.  

Financing

This three-year, $4 million collaboration was co-funded with NTAP (Neurofibromatosis Therapeutic Acceleration Program) and was an extension of the Neurofibromatosis Preclinical Consortium (NFPC), a five-year, $7 million program that concluded in 2013.

Intellectual Property

Children's Tumor Foundation - All rights reserved

Data Sharing

The Donor Privacy Policy is an official policy approved by the Children’s Tumor Foundation Board of Directors. The Children’s Tumor Foundation maintains the highest level of respect for the privacy of our donors. The foundation does not sell, trade, or rent donor data. Further information on specific aspects of the foundation’s commitment to protecting your information is provided below.

Impact/Accomplishment

Studies identified 12 drug targets with promising efficacy, and 16 clinical trials have occurred based on the veracious preclinical data gathered by NFPC and NFTC investigators.

Points of Contact

Toll-free: 1-800-323-7938
E-mail: info@ctf.org

120 Wall Street, 16th Floor
New York, NY 10005-3904
Office: 212-344-6633
Fax: 212-747-0004

Sponsors & Partners

Benjamin Braun, University of California

Karen Cichowski, Harvard Medical School/Brigham and Women’s Hospital

D. Wade Clapp, Indiana University School of Medicine

Nancy Ratner, Cincinnati Children’s Hospital Medical Center

Last Updated: 06/21/2017
The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.
Register your consortium  
All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.